Publications

1.) A novel xenograft mouse model for testing approaches targeting human kappa light-chain diseases.
Ma X, Zhou P, Kugelmass A, Toskic D, Warner M, Lee L, Fogaren T, Godara A, Wang M, Li Y, Yang L, Xu Q, Comenzo RL.
Gene Ther. 2019 Mar 29. doi: 10.1038/s41434-019-0070-y. [Epub ahead of print]
PMID: 30926963

2.) Stigmata of amyloidosis; external manifestations of internal disease.
Chaulagain CP, Comenzo RL.
Br J Haematol. 2019 Mar 27. doi: 10.1111/bjh.15885. [Epub ahead of print] No abstract available.
PMID: 30916377

3.) A Case of T-Cell Large Granular Lymphocytic Leukemia and Renal Immunoglobulin Heavy Chain
Amyloidosis.
Fu J, Lee LX, Zhou P, Fogaren T, Varga C, Comenzo RL.
Am J Case Rep. 2019 Jan 11;20:43-47. doi: 10.12659/AJCR.912282.
PMID: 30631033

4.) Daratumumab binds to mobilized CD34+ cells of myeloma patients in vitro without cytotoxicity or
impaired progenitor cell growth.
Ma X, Wong SW, Zhou P, Chaulagain CP, Doshi P, Klein AK, Sprague K, Kugelmass A, Toskic D,
Warner M, Miller KB, Lee L, Varga C, Comenzo RL.
Exp Hematol Oncol. 2018 Oct 16;7:27. doi: 10.1186/s40164-018-0119-4. eCollection 2018.
PMID: 30356940

5.) Beyond NEOD001 for systemic light-chain amyloidosis.
Varga C, Lentzsch S, Comenzo RL.
Blood. 2018 Nov 1;132(18):1992-1993. doi: 10.1182/blood-2018-07-865857. Epub 2018 Sep 21. No abstract available.
PMID: 30242086

6.) Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With
Deletion of 17p.
Wong SW, Hegenbart U, Palladini G, Shah GL, Landau HJ, Warner M, Toskic D, Jaccard A, Hansen T, Bladé J, Cibeira MT, Kastritis E, Dispenzieri A, Wechalekar A, Varga C, Schönland SO, Comenzo RL.
Clin Lymphoma Myeloma Leuk. 2018 Nov;18(11):e493-e499. doi: 10.1016/j.clml.2018.07.292. Epub 2018 Jul 25.
PMID: 30104177

7.) High-dose melphalan and stem cell transplantation in systemic AL amyloidosis in the era of novel antiplasma cell therapy: a comprehensive review.
Varga C, Comenzo RL.
Bone Marrow Transplant. 2018 Aug 8. doi: 10.1038/s41409-018-0284-4. [Epub ahead of print]
PMID: 30089901

8.) Outcomes of patients with AL amyloidosis and low serum free light chain levels at diagnosis.
Nguyen VP, Rosenberg A, Mendelson LM, Comenzo RL, Varga C, Sanchorawala V.
Amyloid. 2018 Sep;25(3):156-159. doi: 10.1080/13506129.2018.1490261. Epub 2018 Jul 21.
PMID: 30032640

9.) Primary Amyloidosis With Renal Involvement: Outcomes in 77 Consecutive Patients at a Single
Center.
Wong SW, Toskic D, Warner M, Varga C, Moreno-Koehler A, Fein D, Fogaren T, Lee L, Oliver CM,
Guthrie SD, Comenzo RL.
Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):759-766. doi: 10.1016/j.clml.2017.06.004. Epub 2017 Jun 17.
PMID: 28689003

10.) Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple
myeloma.
Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, Weiss BM, Krishnan A, Lentzsch S, Comenzo R, Wang J, Nottage K, Chiu C, Khokhar NZ, Ahmadi T, Lonial S.
Blood. 2017 Aug 24;130(8):974-981. doi: 10.1182/blood-2017-05-785246. Epub 2017 Jun 21.
PMID: 28637662

11.) A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis.
Sanchorawala V, Palladini G, Kukreti V, Zonder JA, Cohen AD, Seldin DC, Dispenzieri A, Jaccard A,
Schönland SO, Berg D, Yang H, Gupta N, Hui AM, Comenzo RL, Merlini G.
Blood. 2017 Aug 3;130(5):597-605. doi: 10.1182/blood-2017-03-771220. Epub 2017 May 26.
PMID: 28550039

12.) Second primary malignancies in multiple myeloma: an overview and IMWG consensus.
Musto P, Anderson KC, Attal M, Richardson PG, Badros A, Hou J, Comenzo R, Du J, Durie BGM, San Miguel J, Einsele H, Chen WM, Garderet L, Pietrantuono G, Hillengass J, Kyle RA, Moreau P, Lahuerta JJ, Landgren O, Ludwig H, Larocca A, Mahindra A, Cavo M, Mazumder A, McCarthy PL, Nouel A, Rajkumar SV, Reiman A, Riva E, Sezer O, Terpos E, Turesson I, Usmani S, Weiss BM, Palumbo A; International Myeloma Working Group.
Ann Oncol. 2018 Apr 1;29(4):1074. doi: 10.1093/annonc/mdx160. No abstract available.
PMID: 28541409

13.) Stem cell transplantation in patients with systemic AL amyloidosis referred for transplant after
suboptimal responses to bortezomib-based initial therapy.
Wong SW, Larivee D, Warner M, Sprague KA, Fogaren T, Comenzo RL.
Bone Marrow Transplant. 2017 Jun;52(6):936-937. doi: 10.1038/bmt.2017.47. Epub 2017 Apr 10. No abstract available.
PMID: 28394371

14.) Addressing Common Questions Encountered in the Diagnosis and Management of Cardiac
Amyloidosis.
Maurer MS, Elliott P, Comenzo R, Semigran M, Rapezzi C.
Circulation. 2017 Apr 4;135(14):1357-1377. doi: 10.1161/CIRCULATIONAHA.116.024438. Review.
PMID: 28373528

15.) Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma.
Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S,
Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P.
Biol Blood Marrow Transplant. 2017 Feb;23(2):269-277. doi: 10.1016/j.bbmt.2016.11.011. Epub 2016 Nov 15.
PMID: 27864161

16.) Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare.
Shah GL, Winn A, Lin PJ, Klein A, Sprague KA, Smith HP, Buchsbaum R, Cohen JT, Miller KB,
Comenzo R, Parsons SK.
Bone Marrow Res. 2016;2016:3645623. Epub 2016 Oct 18.
PMID: 27830092

17.) Investigational agents in immunotherapy: a new horizon for the treatment of multiple myeloma.
Varga C, Laubach JP, Anderson KC, Richardson PG.
Br J Haematol. 2018 May;181(4):433-446. doi: 10.1111/bjh.15116. Epub 2018 May 10. Review.
PMID: 29748955

18.) Current use of monoclonal antibodies in the treatment of multiple myeloma.
Varga C, Maglio M, Ghobrial IM, Richardson PG.
Br J Haematol. 2018 May;181(4):447-459. doi: 10.1111/bjh.15121. Epub 2018 Apr 25. Review.
PMID: 29696629

19.) Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial.
Sanchorawala V, Shelton AC, Lo S, Varga C, Sloan JM, Seldin DC.
Blood. 2016 Aug 25;128(8):1059-62. doi: 10.1182/blood-2016-04-710822. Epub 2016 Jul 5.
PMID: 27381904

20.) Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations.
Varga C, Xie W, Laubach J, Ghobrial IM, O'Donnell EK, Weinstock M, Paba-Prada C, Warren D, Maglio ME, Schlossman R, Munshi NC, Raje N, Weller E, Anderson KC, Mitsiades CS, Richardson PG.
Br J Haematol. 2015 Jun;169(6):843-50. doi: 10.1111/bjh.13382.
PMID: 26032514